Our study shows that apurinic/apyrimidinic endonuclease–redox function drives SRY-Box Transcription Factor 9 activation under reflux and chemotherapy stress, offering a promising therapeutic strategy to target the “undruggable” SRY-Box Transcription Factor 9 transcriptional network to overcome both intrinsic and acquired chemoresistance.
Gastroenterology (AGA) published a clinical update in Research Highlights on 02 Mar 2026.
The item focuses on Targeting APE1-Redox Function Reverses SOX9-mediated Chemoresistance in Esophageal Adenocarcinoma.
Review the original article for the full source wording and details.